NCT05495412 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Bradley JM, Moran FM, Elborn JS
Evidence for physical therapies (airway clearance and physical training) in cystic fibrosis: an overview of five Cochrane systematic reviews. Respir Med. 2006 Feb;100(2):191-201. Review.
Gibson N, Blackmore AM, Chang AB, Cooper MS, Jaffe A, Kong WR, Langdon K, Moshovis L, Pavleski K, Wilson AC
Prevention and management of respiratory disease in young people with cerebral palsy: consensus statement. Dev Med Child Neurol. 2021 Feb;63(2):172-182. doi: 10.1111/dmcn.14640. Epub 2020 Aug 9.
Morris C, Janssens A, Tomlinson R, Williams J, Logan S
Towards a definition of neurodisability: a Delphi survey. Dev Med Child Neurol. 2013 Dec;55(12):1103-8. doi: 10.1111/dmcn.12218. Epub 2013 Aug 5.
Winfield NR, Barker NJ, Turner ER, Quin GL
Non-pharmaceutical management of respiratory morbidity in children with severe global developmental delay. Cochrane Database Syst Rev. 2014 Oct 19;(10):CD010382. doi: 10.1002/14651858.CD010382.pub2. Review.

A Single Case Study to Explore the Impact of Community-based Rebound Therapy on Chest Health Outcomes in School Aged Children and Young People With Neurodisability and Respiratory Issues.

Details for clinical trial NCT05495412

Clinical trial NCT05495412 - References